| Título : |
Late systemic lupus erythematosus-associated insulin resistance syndrome: a rare cause of de novo diabetes mellitus |
| Tipo de documento : |
documento electrónico |
| Autores : |
Carlos Esteban Builes Montaño, ; Carolina Prieto Saldarriaga, ; Clara María Arango Toro, ; Juan Guillermo Gamboa Arroyave, |
| Fecha de publicación : |
2022 |
| Títulos uniformes : |
Case Reports in Medicine
|
| Idioma : |
Inglés (eng) |
| Resumen : |
The association of type B insulin resistance syndrome (TBIRS) due to autoimmune diseases such as systemic lupus erythematosus (SLE) is uncommon. This is partly due to the lack of established criteria for the diagnosis of this resistance. However, some clinical aspects may suggest that the diagnosis does not necessarily have to be positive insulin receptor antibodies as such patients could respond to immunosuppressive treatment. Methods. We describe a case and have performed a literature review on PubMed/MEDLINE, EMBASE, and Google Scholar bibliographic databases to identify all case reports. All available studies from January 1975 through December 2020 were included. Data collected were tabulated, and outcomes were analyzed cumulatively. Results. Thirty-one cases of TBIRS associated with SLE have been described. These patients presented with catabolic symptoms and hyperglycemia in most cases, with an average time from the onset of symptoms of four months. In addition to that clinical characteristics related to SLE were variable, along with certain common characteristics such as acanthosis in 60% of patients. Almost all the patients had antibodies against insulin receptors. The insulin doses required by the patients ranged from 450 to 25,000 U daily. Remission was achieved in 80% of the patients with a two-year follow-up. Most patients associated with late-onset SLE, like our patient, achieved metabolic control after immunosuppressive treatment. Conclusion. High insulin resistance in patients with de novo diabetes mellitus (DM) without obesity should be considered as a possible clinical manifestation of an autoimmune disease such as SLE, with a good metabolic response to the immunosuppressive management established. |
| Mención de responsabilidad : |
José C Alvarez-Payares, Daniel Ribero, Luis Rodríguez, Carlos E Builes, Carolina Prieto, Clara Arango, Juan G Gamboa, Cristian Alvarez-Payares |
| Referencia : |
Case Rep Med. 2022 Oct 14;2022:4655804. |
| DOI (Digital Object Identifier) : |
10.1155/2022/4655804 |
| PMID : |
36275943 |
| Derechos de uso : |
CC BY |
| En línea : |
https://www.hindawi.com/journals/crim/2022/4655804/ |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6075 |
Late systemic lupus erythematosus-associated insulin resistance syndrome: a rare cause of de novo diabetes mellitus [documento electrónico] / Carlos Esteban Builes Montaño, ; Carolina Prieto Saldarriaga, ; Clara María Arango Toro, ; Juan Guillermo Gamboa Arroyave, . - 2022. Obra : Case Reports in MedicineIdioma : Inglés ( eng) | Resumen : |
The association of type B insulin resistance syndrome (TBIRS) due to autoimmune diseases such as systemic lupus erythematosus (SLE) is uncommon. This is partly due to the lack of established criteria for the diagnosis of this resistance. However, some clinical aspects may suggest that the diagnosis does not necessarily have to be positive insulin receptor antibodies as such patients could respond to immunosuppressive treatment. Methods. We describe a case and have performed a literature review on PubMed/MEDLINE, EMBASE, and Google Scholar bibliographic databases to identify all case reports. All available studies from January 1975 through December 2020 were included. Data collected were tabulated, and outcomes were analyzed cumulatively. Results. Thirty-one cases of TBIRS associated with SLE have been described. These patients presented with catabolic symptoms and hyperglycemia in most cases, with an average time from the onset of symptoms of four months. In addition to that clinical characteristics related to SLE were variable, along with certain common characteristics such as acanthosis in 60% of patients. Almost all the patients had antibodies against insulin receptors. The insulin doses required by the patients ranged from 450 to 25,000 U daily. Remission was achieved in 80% of the patients with a two-year follow-up. Most patients associated with late-onset SLE, like our patient, achieved metabolic control after immunosuppressive treatment. Conclusion. High insulin resistance in patients with de novo diabetes mellitus (DM) without obesity should be considered as a possible clinical manifestation of an autoimmune disease such as SLE, with a good metabolic response to the immunosuppressive management established. |
| Mención de responsabilidad : |
José C Alvarez-Payares, Daniel Ribero, Luis Rodríguez, Carlos E Builes, Carolina Prieto, Clara Arango, Juan G Gamboa, Cristian Alvarez-Payares |
| Referencia : |
Case Rep Med. 2022 Oct 14;2022:4655804. |
| DOI (Digital Object Identifier) : |
10.1155/2022/4655804 |
| PMID : |
36275943 |
| Derechos de uso : |
CC BY |
| En línea : |
https://www.hindawi.com/journals/crim/2022/4655804/ |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6075 |
|  |
Inicio
Clasificado(s) por (Año de edición descendente) Refinar búsquedaLate systemic lupus erythematosus-associated insulin resistance syndrome: a rare cause of de novo diabetes mellitus / Carlos Esteban Builes Montaño ; Carolina Prieto Saldarriaga ; Clara María Arango Toro ; Juan Guillermo Gamboa Arroyave
